拉努斯vs沙佩科恩斯-回合游戏

拉努斯vs沙佩科恩斯

巴塞scvs拉普大学比分

About Us

Teikoku Pharma USA located in San Jose California and headquartered in Kagawa Japan, is a pharmaceutical company focused on the research and development of treatments for CNS, Pain Management and Oncology.  Founded in 1997, the company successfully developed Lidocaine 5% patch worldwide under Lidoderm®, Lidotop® and  Versatis® brands.  To date, 2 billion Lidocaine 5% patches have been distributed in 59 countries.  TPU recently also received NDA approval for Non-alcohol Docetaxel injection currently available in the US.

Latest News and Events

May 30, 2018

Teikoku Pharma USA and Link Health Enter into License Agreement for Lidoderm® in China
SAN JOSE, Calif.,May 30, 2018--Teikoku Pharma USA Inc. (“TPU”) today announced that it has entered into an exclusive license agreement with Link Health Group LTD (“Link Health”) to develop market, sell, and distribute TPU’s flagship product, Lidoderm®, in China. Lidoderm® offers relief of the pain associated with post-herpetic neuralgia (“PHN”). It is a combination of lidocaine in a soft hydrogel plaster combining efficacious treatment with proven tolerability, safety and simple handling.

Read more | View All

Innovation

Teikoku is building a robust pipeline of drug candidates which may expand the reach and benefit of existing therapeutics.   

Learn more about our pipeline.

Products

Teikoku USA has two FDA and one EMEA approved products in the market.
Learn more about our approved products.

Development

We employ our Hydrohesive, Matrix and other drug delivery technologies to expand our product pipeline.
Learn More About Our Technologies.

友情链接: 7月27日中国vs菲律宾   掘金vs76人录像   2016欧文vs库里总决赛   纽约城vs费城联   北方星vs海湾魔法   2017鲁能vs辽宁集锦   圣何塞vs盐湖城   科克城vs拉纳卡集锦   贝基拉vs   活塞vs火箭一月二十号   莱昂vs瓦哈卡比分   阿森纳 vs 埃弗顿 竞猜   德赫亚vs诺伊尔   韦斯屈莱vs古比斯分析   2011巴萨vs皇马16轮   韦斯屈莱vs古比斯分析   澳大利亚vs意大利全场   baiduxml